Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old, of any gender
• People with a good general health and activity level (rated 0 or 1 on a standard medical scale, meaning fully active or able to carry out light work)
• People who have been confirmed through tissue or cell testing to have non-small cell lung cancer (NSCLC) at stage II, IIIA, or a specific type of stage IIIB, where the cancer is expected to be fully removable by surgery, including nearby lymph nodes no larger than 2cm in short diameter
• People who have at least one measurable tumour or affected lymph node of a minimum size, as measured on a CT scan using standard criteria
• People who have not previously received any cancer treatment, including radiotherapy, chemotherapy, surgery, or targeted therapy
• People whose lung function is strong enough to safely undergo surgery with the goal of completely removing the cancer
• People whose blood test results meet specific minimum thresholds for white blood cells, haemoglobin, and platelets (without recent transfusions or blood-boosting medications)
• People whose liver and kidney function test results fall within acceptable ranges as defined by the trial

Who may not be able to join:

• People whose cancer has a known EGFR or ALK gene mutation
• People whose tumour has grown into nearby critical structures such as the heart, major blood vessels, windpipe, voice nerve, food pipe, spine, or the upper part of the lung near the shoulder
• People who have taken immune-suppressing medications in the 4 weeks before the first study treatment (with some exceptions for low-dose steroids and inhaled or nasal sprays)
• People who have used herbal medicines or other substances known to affect the immune system in the 4 weeks before the first study treatment (with some exceptions)
• People who have had a different type of cancer in the 5 years before joining the trial
• People who have received a live vaccine within 4 weeks before the first study treatment, or who plan to receive one during the trial
• People who are currently taking part in another clinical trial involving an investigational treatment, or who received such a treatment within 4 weeks before starting this trial, or who have not fully recovered from side effects of a previous medical procedure
• People who have had a serious infection requiring intravenous antibiotics or antifungal/antiviral medications within 4 weeks before the first dose, or who have an unexplained fever above 38.5°C at the time of screening
• People who have a history of, or suspected, pneumonia, interstitial lung disease, or any lung condition that would interfere with breathing tests
• People with an active autoimmune disease or a history of autoimmune disease (people with childhood asthma that resolved completely without treatment, or with a skin condition called vitiligo, may still be considered)
• People with immune system deficiencies such as HIV infection, active hepatitis B or C, or both hepatitis B and C together, or liver cirrhosis related to alcohol use
• People with significant heart conditions, including moderate-to-severe heart muscle disease, poorly controlled irregular heartbeat, heart failure of grade III or IV, a heart ejection fraction below 50%, or a heart attack or serious heart event within the 6 months before joining
• People whose liver enzyme levels (ALT or AST) are more than 2.5 times the upper normal limit, or whose bilirubin is more than 1.5 times the upper normal limit, or whose creatine kinase is more than 3 times the upper normal limit, or who have had a significant bleeding or blood clot event
• People who have previously received an organ transplant or bone marrow/stem cell transplant from another person
• People with a known allergy or sensitivity to the study drug or any of its ingredients
• People with any other condition that the trial doctor believes could be harmful or prevent them from completing the study requirements

Important: Always verify eligibility with the trial site directly before applying.